

Curriculum Vitae

Name: Wei DUAN **Date of Birth:** Nov., 1957

Nationality: Australian

Present Appointment: Professor

Contact Information:

Dr Wei Duan

School of Medicine

Deakin University, Waurn Ponds, Victoria, 3217, Australia

Tel:+61 3 5227 1149, **Fax:**+61 3 5227 2945. **E-mail:** wduan@deakin.edu.au



Research Areas:

Aptamer technology, targeted drug delivery, nanomedicine, molecular imaging, cancer biology and pharmacology.

Teaching Areas:

Biochemistry, Molecular Cell Biology, Nanomedicine; Biotechnology.

Academic/Professional Qualifications:

Apr. 1988--Aug. 1991 Department of Biochemistry & Molecular Biology,
Faculty of Medicine, The University of Melbourne, Australia
Degree conferred: Ph.D.

Feb. 1978--Dec. 1982 Department of Medicine,
Shanghai University of Traditional Chinese Medicine,
P.R. China
Degree conferred: MBBS.

Career History:

- *Physician* (1982-1984), Shanghai TV Corporation, P.R. China
- *Lecturer* (1986-1988), Shanghai Medical Staff College, P.R. China
- *Research Fellow* (1991-1992), University of Melbourne, Australia
- *Senior Research Officer* (1993-1994), Clinical Neuroscience Centre, Royal Melbourne Hospital, University of Melbourne, Australia
- *Research Fellow* (1995-1998), University of Melbourne, Australia
- *Assistant Professor* (1998-2006), National University of Singapore
- *Associate Professor* (2006-2010), Deakin University, Australia
- *Professor* (2011--), Deakin University, Australia

Professional Qualifications/membership;

October., 1987:

Elected Member, Chinese Medical Association, Internal Medicine.

September, 1987:

Elected Member, Chinese Association of Traditional Chinese Medicine, Internal Medicine.

Professional/Consulting Activities:

Vice President, Singapore Society for Biochemistry & Molecular Biology (2000).

Administrative Duties:

(since initial appointment to Deakin):

- Deputy Chair, Deakin University Laboratory Safety Committee (2010-).
- Member, Deakin University Laboratory Safety Committee (2006-).
- High Degree by Research (Graduate studies) Coordinator for School of Medicine (2008-2009)
- Member, FHMNBS Human Research Ethics Committee (2008-)

Grants Obtained:

1. Wei Duan & Lingxue Kong, “Smart bombing of cancer stem cells using aptamer-guided nanoliposomal siRNA”, Australian Government Department of Innovation, Industry, Science and Research, Australia-India Strategic Research Fund Programme--Indo-Australia Science and Technology Fund. # ST040007. \$400,000, 2010-2014.

2. Wei Duan: Deakin University Strategic Research Centre (Molecular Medial Research), Nanomedicine fund, **\$18,000**. 2010.

3. Wei Duan, Andrew Danks, Michael Famulok, Ling Xue Kong, Peter Brothie
Victorian Cancer Agency Platform Technology Capacity Building Grant “Establishment of an aptamer-based technology platform for molecular targeting of cancer stem cell”, Department of Human Services, Victorian Government. **\$149,996**, 2009-2010.

4. Wei Duan, “Exploration of Complementary and Alternative Medicines for the Management and Prevention of Type 2 Diabetes”, **\$13,000**. Biomolecular Nutrition and Molecular Medicine cluster, Faculty of Health, Medicine Nursing and Behavioural Sciences, Deakin University, 2007.

5. Wei Duan, “Establishment of an aptamer technology platform for molecular medicine”, **\$14,000**. 2007 Faculty of Health, Medicine Nursing and Behavioural Sciences Research Development Grants, Deakin University.

6. Wei Duan, “LAS-4000 Imaging System for Nanomedicine”, **\$40,000**, Dean's special support to Nanomedicine Program, Faculty of Health Medicine Nursing and Behavioural Sciences, Deakin University. 2007.

7. Wei Duan, “A Multi-detector liquid scintillation and luminescence counter for Nanomedicine”, **\$36,442**, National Health & Medical Research Council (NHMRC) Infrastructure Support, Deakin University, 2007.

8. Wei Duan, “Anticancer role of Protein Kinase C α in pituitary tumours”, **\$13,000**. Deakin University Central Research Grants Scheme, 2007.

9. Wei Duan, Lingxue Kong and David Cahill, “Nanomedicine and Nanobiotechnology”, **\$65,000**. Deakin University Research Infrastructure Support Scheme, 2008,

10. Wei Duan, “Link and Learn Travel Grants”, 2008. **\$5000**. Victorian Cancer Agency, Department of Human Services, Victoria. Australia.

11. W Duan, A Danks, SK Lo, Q.T. Li

“A novel- tumour-targeting nanoliposome drug deliver system for the treatment of malignant gliomas”. 2008-2010 (\$426,000),
National Health & Medical Research Council, Australia (NHMRC) project grant, ID: 479505

12. Wei Duan & Qipeng Guo

“Developing molecularly targeted polymer nanoparticles for cancer therapeutics and diagnostics”
2007-2010, **\$325,419**.

Australian Government Department of Innovation, Industry, Science and Research, Australia-
India Strategic Research Fund. #ST01-0013.

13. Wei Duan, B. Crotty, A. Ward, Geelong Community Foundation, Victoria, Australia.

“Development of medical research capacity at Deakin Medical School—a fluorescence microscope”. **\$30,000**. June, 2007.

14. W Duan, National Medical Research Council, Singapore, "A novel therapeutic target of prostate cancer: role of PRK1 kinase in the progression and invasion of prostate cancer", (3-year support, \$215,102). August 2004—August, 2007.

15. W. Duan, T. Dokland, Biomedical Research Council, Singapore (A*STAR), "Determination of 3-dimensional structure of isozymes from protein kinase C superfamily by X-ray crystallography", (3-year support, \$754,500). June 2002—March 2006.

16. W. Duan, National Medical Research Council, Singapore, " Regulation of Serine/Threonine Protein Kinase PRK1 in Health and Disease", (3-year support, \$296,000). September 2001—September, 2004.

17. W. Duan, National University of Singapore (Academic Research Fund), " Protein serine/threonine kinase PRK1 and insulin signalling". August, 2000--August 2003. (\$175,000).

18. W. Duan, National University of Singapore (Academic Research Fund), " Structure-function relationship analysis of transthyretin--a thyroid hormone transport protein". (\$67,500, 1999---2001).

Grant Review:

1—1995, National Health & Medical Research Council, Australia

2—2001, Biomedical Research Council, Singapore

3—2002, Academic Research Fund (National University of Singapore)

4—2002 Biomedical Research Council, Singapore

5—2007, National Heart Foundation, Australia.

6—2010, Qatar National Research Fund.

7—2010, Canada Foundation for Innovation.

8—2010, National Health & Medical Research Council, Australia, project grant assessor.

Invited Addresses

1. Wei Duan, “A Novel Paradigm in Mammalian Cell Signaling”, Signal Transduction—Targets for effective therapeutics, Cambridge Healthtech Institute, Seaport Hotel, Boston, MA, USA, November 8-9, 2004. [My talk was reviewed in “Rounding up the usual suspects: protein kinases as the therapeutic targets”, S.B. Shears, *Drug Discovery Today*.10(4):240-242, 2005.]

2. **Wei Duan**, "Signaling via a novel integral plasma membrane pool of protein kinase C", The Hunter Meeting of Cell Biology, Sydney, Australia, 6-8 April, 2005.
3. **Wei Duan**, "Herbal Medicine In Australia—Transforming Ancient Remedy With Nanotechnology", 59th Indian Pharmaceutical Congress, Varanasi-221 005, Uttar Pradesh, India, 20-23 December, 2007.
4. **Wei Duan**, "Development of Molecular Medicine that Specifically Targets Protein Kinase C in Heart Failure", 10th South China International Congress of Cardiology, Dongfang Hotel, Guangzhou, China, 10-13, April, 2008.
5. **Wei Duan**, "Targeted drug delivery using RNA aptamer and nanoparticles—the miracle of nanomedicine for the 21st century". VII Thailand Research Fund (TRF) Annual Congress. October 16-18, 2008, Holiday Inn Resort Regent Beach, Cha-Am, Thailand.
6. **Wei Duan**, "Aptamer therapeutics: the 21st century's magic bullet of nanomedicine", Second International Conference on Drug Discovery and Therapy'. February 1-4, 2010. Dubai, United Arab Emirates.
7. **Wei Duan**, "Nucleic acid aptamer: the pearl in the crown of nanomedicine for molecular imaging of cancer", The 4th International Symposium on Bioanalysis, Biomedical Engineering and Nanotechnology (ISBBN 2010), Hunan University in Changsha, Hunan, China (June 3-6, 2010).
8. **Wei Duan**, RNA Aptamer: The Next Generation of Cancer Stem Cell-targeted Molecular Imaging, **BIT's 9th Annual Congress of International Drug Discovery Science and Technology** --- Re-think Drug Innovations in Green-Eco Era (Session 7-1-2: Nucleic Acid Therapeutics), November 3-6, 2011, Shenzhen, China;

Manuscript Reviewing

2010

- British Journal of Nutrition
- European Journal of Public Health
- Journal of Pediatrics
- Current Medicinal Chemistry
- Drug Metabolism Letters

2009

- Gene Therapy and Molecular Biology
- Molecular Cancer
- Neurosignals
- Current Medicinal Chemistry
- International Journal of Cardiology

2008

- Current Pharmaceutical Design
- Molecular Cancer
- Trends in Endocrinology and Metabolism
- Drug Metabolism Letters

- Nature Protocols
- Journal of Histochemistry & Cytochemistry
- Tissue Engineering

2007

- American Journal of Physiology - Heart and Circulatory Physiology
- Health Promotion International
- Current Drug Metabolism
- Cytokine
- Nature Protocols

Research Award

“Researcher of the Year Awards 2008--Biotechnology Award” from Department of Innovation, Industry and Regional Development, State Government of Victoria and Smart Geelong Network.

Publications in peer reviewed journals:

Note: **ERA** (The Excellence in Research for Australia) journal ranking is a system used by Australian Government's Australian Research Council (<http://www.arc.gov.au/era/default.htm>) to rank journals, where A* ≈top 5%; A ≈next 15%; B ≈next 25%; C the rest ≈55%.

REVIEWS

1. **W. Duan**, "Enhancers and the Control of Gene Expression", *Advances in Medicine--Mol. Biol.* (Beijing) 5:52-56, 1985.
2. G. Schreiber, A.R. Aldred, and **W. Duan**, "Choroid Plexus, Brain Protein-Homeostasis and Evolution". *Today's Life Science* 4:22-28, 1992.
3. Southwell BR, Tu GF, **Duan W**, Achen M, Harms PJ, Aldred AR, Richardson SJ, Thomas T, Pettersson TM, Schreiber G. "Cerebral expression of transthyretin: evolution, ontogeny and function", *Acta Med Austriaca*.;19 Suppl 1:28-31, 1992. (Impact Factor: 0.439). Times Cited: 4.
4. Shufeng Zhou, Eli Chan, **Wei Duan**, Min Huang and Yu-Zong Chen, "Drug bioactivation covalent binding to target proteins and toxicity relevance", *Drug Metab. Rev.* 37(1):241-213, 2005 (Impact Factor: 6.283; ERA: A). Times Cited: 69.
5. Zeping Hu, Xiaoxia Yang, Paul Chi Lui Ho, Sui Yung Chan, Paul Wan Sia Heng, Eli Chan, **Wei Duan**, Hwee Ling Koh, Shufeng Zhou, "Herb-drug interactions--A literature review ". *Drugs*, 65(9):1239-1282. 2005 (Impact Factor: 4.611; ERA: A). Times Cited: 146.
6. Zhou S, Yung Chan S, Cher Goh B, Chan E, **Duan W**, Huang M, McLeod HL, "Mechanism-based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs", *Clinical Pharmacokinetics*, 44:279-304, 2005 (impact Factor: 5.453; ERA: A). Times Cited: 134..
7. Zhang J, Tian Q, Chan SY, **Duan W**, Zhou S."Insights into oxazaphosphorine resistance and possible approaches to its circumvention.", *Drug Resist Updat.* 8(5):271-297, 2005. (Impact Factor: 6.172; ERA: B). Times Cited: 22.

8. X. Yang, Z. Hu, S. Y. Chan, E. Chan, B. C. Goh, **W. Duan** and S. Zhou, "Novel agents that potentially inhibit irinotecan-induced diarrhea", *Curr. Med. Chem.*, 12:1343-1358, 2005. (Impact Factor; 4.409; ERA: B). Times Cited: 9.
9. Zhang J, Tian Q, Yung Chan S, Chuen Li S, Zhou S, **Duan W**, Zhu YZ., "Metabolism and transport of oxazaphosphorines and the clinical implications", *Drug Metab Rev.* 37(4):611-703. 2005. (Impact Factor = 6.283; ERA: A). Times Cited: 38.
10. Quan Tian, Jing Zhang, Eli Chan, **Wei Duan**, Shufeng Zhou, "Multidrug resistance proteins (MRPs) and implication in drug development", *Drug Develop. Res.*, 64(1):1-18, 2005. (IF= 0.758; ERA: B). Times Cited: 10.
11. Ze-Ping Hu, Xiao-Xia Yang, Sui Yung Chan, **Wei Duan**, Hong-Yuan Yang, Yi-Zhun Zhu, and Shu-Feng Zhou, "Drug-Herb Interactions: Eliminating Toxicity with Hard Drug Design", *Current Pharmaceutical Design*, 12(35):4649-4664, 2006. (Impact Factor: 5.385; ERA: A). Times Cited: 12.
12. Yupeng He, **Wei Duan** & S.-L. Tan, "Emerging Host Cell Targets for Hepatitis C Therapy", *Drug Discovery Today*, 12(5-6):209-17, 2007 (Impact Factor: 7.755, ERA: C). Times Cited: 11.
13. Liang J, Huang M, **Duan W**, Yu XQ, Zhou S., "Design of new oxazaphosphorine anticancer drugs.", *Current Pharmaceutical Design*. 13(9):963-978, 2007. (Impact Factor: 5.385; ERA: A). Times Cited: 7.
14. M.R. Lee, **Wei Duan**, & S.L. Tan. "Protein kinase C isozymes as potential therapeutic targets in immune disorders.", *Expert Opin Ther Targets*. 12 (5):535-552, 2008. (IF=3.333; ERA: B). Times Cited: 5.
15. Zhou SF, Wang LL, Di YM, Xue CC, **Duan W**, Li CG, Li Y., "Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development", *Curr Med Chem*.15(20):1981-2039, 2008. (IF=4.944; ERA: B). Times Cited: 47.
16. Zhou S.F, Di YM, Chan E, Du YM, Chow VD, Xue CC, Lai X, Wang JC, Li CG, Tian M, **W Duan**. "Clinical pharmacogenetics and potential application in personalized medicine". *Curr Drug Metab*. 9(8):738-784, 2008. (IF=4.49; ERA: A*). Times Cited: 39.
17. Mo SL, Liu YH, **Duan W**, Wei MQ, Kanwar JR, Zhou SF., "Substrate Specificity, Regulation, and Polymorphism of Human Cytochrome P450 2B6". *Curr Drug Metab*. 10(7):730-753, 2009. (IF=4.35; ERA: A*). Times Cited: 4.
18. Zhou SF, Chan E, Zhou ZW, Xue CC, Lai X, **Wei Duan**, "Insights into the Structure, Function, and Regulation of Human Cytochrome P450 1A2." *Curr Drug Metab*. 10(7): 713-729, 2009 (IF=4.35; ERA: A*). Times Cited: 4.
19. Y.C. Lim, A.Z. Kouzani, **W. Duan**. "Aptasensors: A Review", *Journal of Biomedical Nanotechnolog*, 6(2):93–105, 2010 (Impact Factor: 1.588; ERA=C). Times Cited: 1.
20. S-M He, C G Li, F-Q Xing, J-P Li, E Chan, **W. Duan**, S-F Zhou, "Disposition Pathways and Pharmacokinetics of Herbal Medicines in Humans", *Current Medicinal Chemistry*, 17:4072-4113, 2010. (IF= 4.823) (IF=4.944; ERA: B).

21. Y.C. Lim, A.Z. Kouzani, **W. Duan**, "Lab-on-a-chip: A component view", *Microsystem Technologies-Micro-And Nanosystems-Information Storage And Processing Systems* 16(12) 1995-2015, 2010. (IF= 1.025, ERA=B).

22. Sarah Shigdar, Jasmina Luczo, Ming Q. Wei, Richard Bell, Andrew Danks, Ke Liu & **Wei Duan** "Aptamer Therapeutics: The 21st Century's Magic Bullet of Nanomedicine, *The Open Conference Proceedings Journal*, 1:118-124, 2010.

Book Chapters

1. Aldred AR, Pettersson TM, Harms PJ, Richardson SJ, **Duan W**, Tu GF, Achen MG, Nicol S, Schreiber G, "The position of the echidna in the evolution of thyroid hormone-binding plasma proteins", p44-52, in "*Platypus and echidnas*", Augee ML, ed., The Royal Zoological Society of NSW, Sydney, 1992

2. XY Ji, BKH Tan, SH Huang, M. Whiteman, YC Zhu, W Linz, **W. Duan** and YZ Zhu. "Effects of *Salvia miltiorrhiza* in ischemic myocardium in experimental rats". In: B Tan, BH Bay, and YZ Zhu eds. *Novel compounds from natural products in new millenniums: potentials and challenges*. p.183-195, World Scientific Press, Singapore, 2004 (ISBN 981-256-113-7).

3. Y.C. Lim, A.Z. Kouzani, and **W. Duan**, "Aptasensors Design Considerations". In Communications in Computer and Information Science, Volume 51, Computational Intelligence and Intelligent Systems, pp. 118–127. Z. Cai, Z. Li, Z. Kang, and Y. Liu. eds. Springer-Verlag Berlin, Heidelberg, 2009 (ISBN 978-3-642-04961-3).

4. Shu-Feng Zhou, Jun-Ping Liu, Ming Qian Wei & **Wei Duan**. "Chapter 5. Role of Multidrug Resistance Associated Proteins in Drug Development". In: Multidrug Resistance: A Global Concern. Asad Khan, Ed., Bentham Science Publishers Ltd, New York, July, 2010.

5. Sarah Shigdar, Adam Smith and **Wei Duan**, "APTAMERS AND NANOMEDICINE", in *Nanotechnology in human health Care*. (ISBN: 981426721X), Sahoo, S. (ed), Pan Stanford Publishing, Singapore, (Scheduled 2010).

6. "Cancer Gene Therapy". In: Gene Therapy - developments and future perspectives. Ed. ISBN 978-953-307-617-1. InTech, Rijeka, Croatia.

Papers in Refereed Journals

1. **W. Duan**, T. Cole and G. Schreiber, "Cloning and Nucleotide Sequencing of Transthyretin (Prealbumin) cDNA from Rat Choroid Plexus and Liver". *Nucl. Acids Res.* 17:3979, 1989. (Impact Factor: 7.260; ERA: A). Times Cited: 29.

2. G.-T. Tu, T. Cole, **W. Duan** and G. Schreiber, "The Nucleotide Sequence of Transthyretin cDNA Isolated from a Sheep Choroid Plexus cDNA Library". *Nucl. Acids Res.* 17:6384, 1989. (Impact Factor: 7.260; ERA: A). Times Cited: 29.

3. **W. Duan**, M.G. Achen, S.J. Richardson, R.E.H. Wettenhall, M.C. Lawrence, A. Jaworowski and G. Schreiber, "Isolation, Characterisation, cDNA Cloning and Gene Expression of Chicken Transthyretin: Implications for the Evolution of Structure and Function of Transthyretin in Vertebrates". *Eur. J. Biochem.* 200:679-687, 1991. (Impact Factor: 3.0; ERA: B). Times Cited: 68.

4. B.R. Southwell, **W. Duan** and G. Schreiber, "Ontogenesis of Transthyretin Gene Expression in Chicken Choroid Plexus and Liver". *Comp. Biochem. Physiol.* 100B:329-338, 1991. (Impact factor: 1.579; ERA: B) Times Cited: 39.
5. **W. Duan** and G. Schreiber, "Expression of Retinol-Binding Protein mRNA in Mammalian Choroid Plexus". *Comp. Biochem. Physiol.* 101B:399-406, 1991. (Impact factor: 1.579; ERA: B), Times Cited: 9.
6. G. Schreiber, T.M. Pettersson, B.R. Southwell, A.R. Aldred, P.J. Harms, S.J. Richardson, R.E.H. Wettenhall, **W. Duan**, and S. C. Nicol, "Transthyretin Expression Evolved More Recently In Liver Than In Brain". *Comp. Biochem. Physiol.* 105B:317-325, 1993. (Impact factor: 1.579; ERA: B), Times Cited: 31.
- 7 S.J. Richardson, A.J. Bradley, **W. Duan**, B.R. Southwell, L. Selwood and G. Schreiber, "The expression of the transthyretin gene in liver evolved during the radiation of diprotodont marsupials in Australia". *Gen. & Comp. Endocrinol.* 90:177-182, 1993. (Impact factor: 1.844; ERA: C). Times Cited: 19.
8. M.G. Achen, **W. Duan**, T.M. Pettersson, P.J. Harms, S.J. Richardson, M.C. Lawrence, R.E.H. Wattenhall, A.R. Aldred and G. Schreiber, "Transthyretin gene expression in choroid plexus first evolved in reptiles". *Am. J. Physiol.* 265:R982-R989, 1993. (Impact factor: 4.431; ERA: A). Times Cited: 32.
9. B.R. Southwell, **W. Duan**, D. Alcorn, C. Brack and G. Schreiber, "Thyroxine transport to the brain: role of protein synthesis by the choroid plexus". *Endocrinology* 133:2116-2126, 1993. (Impact Factor 5.063; ERA: A*). Times Cited: 82.
10. S.J. Richardson, A.J. Bradley, **W. Duan**, P.J. Harms, R.E.H. Wettenhall, S. Nicol, S.C. Donnellan and G. Schreiber, "The evolution of thyroxine-binding plasma proteins in marsupials and other vertebrates". *Am. J. Physiol.* 266:R1359-R1370, 1994. (Impact Factor 3.627; ERA: A). Times Cited: 69.
11. C. Brack, **W. Duan**, and G. Schreiber, "Wallaby transthyretin". *Comp. Biochem. Physiol.* 110B:523-529, 1995. (Impact factor: 1.579; ERA: B). Times Cited 15.
12. **W. Duan**, S.J. Richardson, J.J. Babon, R.J. Heyes, B.R. Southwell, P.J. Harms, R.E.H. Wettenhall, K.M. Dziegielewska, L. Selwood, A.J. Bradley, C. Brack and G. Schreiber, "Evolution of transthyretin in marsupials". *Eur. J. Biochem.* 227:396-406, 1995. (Impact Factor: 3.0; ERA: B). Times Cited: 30.
- 13 **W. Duan**, S.J. Richardson, J. Kohrle, L. Chang, B.R. Southwell, P.J. Harms, C.M. Back, T.M. Pettersson and G. Schreiber, "Binding of thyroxine to pig transthyretin, its cDNA structure and other property". *Eur. J. Biochem.* 230:977-986, 1995. (Impact Factor: 3.0; ERA: B). Times Cited: 21.
14. D.G. Walker, **W. Duan**, E.A. Popovic, A.H. Kaye, F.H. Tomlinson and M. Lavin, "Homozygous deletions of the MTS1 gene in the progression of human astrocytomas". *Cancer Research* 55:20-23, 1995. (Impact Factor: 8.649; ERA: A*). Times Cited 135.

15. D.G. Walker, **W. Duan**, A.H. Kaye and M.F. Lavin, "Homozygous deletions of the MTS1 gene are rare in non-astrocytic brain tumors". *Biochem. Biophys. Res. Commun.* 211:404-409, 1995. (Impact Factor: 2.946; ERA: B). Times cited: 2.
16. **W. Duan**, B. Sun, T.W. Li, B.J. Tan, M.K. Lee, T.S. Teo. "Cloning and characterization of AWP1, a novel protein that associates with serine/threonine kinase PRK1 in vivo". *Gene*. 256:113-121, 2000. (Impact Factor: 2.705; ERA: B). Times Cited: 17.
17. T. Li, **W. Duan**, H. Yang, M. Lee, F. Bte Mustafa, B. Lee, T. Teo. "Identification of two proteins, S14 and UIP1, that interact with UCH37." *FEBS Lett.* 88:201-205, 2001. (Impact Factor: 3.912; ERA: B). Times Cited: 12.
18. R. Jin, V. T. Chow, S. T. Dheen, **W. Duan**, P. Tan and B.-H. Bay "Metallothionein 1 and 2 isoforms in breast cancer cells: differential expression with invasive phenotype and identification of variants", *Carcinogenesis*, 23:81-86, 2002. (Impact Factor: 5.405; ERA: A). Times Cited: 85.
19. J.S. Armstrong, H. Yang, **W. Duan** and M. Whiteman, "Cytochrome bc1 regulates the mitochondrial permeability transition by two distinct pathways", *Journal of Biological Chemistry*, 279:50420-50428, 2004. (Impact Factor: 6.482; ERA: A*). Times Cited: 31.
20. W. Fan, J. Ding, **W. Duan** and Y. M. Zhu, "The influence of magnetic fields exposure on neurite outgrowth in PC 12 rat pheochromocytoma cells", *Journal of Magnetism and Magnetic Materials*, 282:325-328, 2004. (Impact factor 1.031; ERA: C). Times Cited: 0.
21. J. Sun, S. H. Huang, B. K.-H. Tan, M. Whiteman, Y. C. Zhu, Y. J. Wu, Y. Ng, **W. Duan** and Y. Z. Zhu, "Effects of purified herbal extract of *Salvia miltiorrhiza* on ischemic rat myocardium after acute myocardial infarction", *Life Sciences*, 76:2849-2860, 2005 (Impact Factor: 2.158; ERA: B). Times Cited: 40.
22. Yimin Zhu, Donna B. Stolz, Fengli Guo, Mark A. Ross, Simon C. Watkins, Bee Jen Tan, Robert Z. Qi, Ed Manser, Qiu Tian Li, Boon Huat Bay, Tian Seng Teo and **Wei Duan**, "Signaling via a novel integral plasma membrane pool of a serine/threonine protein kinase PRK1 in mammalian cells", *The FASEB Journal*, 18:1722-1724, 2004. (Impact factor : 7.172; ERA: A). Times Cited: 9.
23. Wee Guan Lim, Yimin Zhu, Chern-Hoe Wang, Bee Jen Tan, Jeffrey Armstrong, Terje Dokland, Hongyuan Yang, Yi-Zhun Zhu, Tian Seng Teo and **Wei Duan**, "The last five amino acid residues at the C-terminus of PRK1/PKN is essential for full lipid responsiveness", *Cellular Signalling*, 17:1084-1097, 2005. (Impact Factor 5.185; ERA: B). Times Cited: 6.
24. Yimin Zhu, Wee Guan Lim, Bee Jen Tan, Tian Seng Teo & **Wei Duan**, "Identification of an integral plasma membrane pool of protein kinase C in mammalian tissues and cells", *Cellular Signalling*, 17:1125-1136, 2005. (Impact Factor 5.185; ERA: B). Times Cited: 1.
25. Yimin Zhu, Qihan Dong, Bee Jen Tan, Wee Guan Lim, Shufeng Zhou and **Wei Duan**, "The PKC α -D294G mutant found in pituitary and thyroid tumors fails to transduce extracellular signals", *Cancer Research*, 65: 4520-4524, 2005. (Impact Factor: 8.649; ERA: A*). Times Cited: 9.
26. Z. Hu, X. Yang, P. C. Ho, E. Chan, S. Y. Chan, C. Xu, X. Li, Y. Zhu, **W. Duan**, X. Chen, M. Huang, and S. Zhou, "St. John's wort modulates the toxicities and pharmacokinetics of CPT-11

(irinotecan) in rats”, *Pharmaceutical Res.* 22(6):902-914, 2005. (Impact Factor; 2.940; ERA: A). Times Cited: 16.

27. Y. Gao, H. Gao, E. Chan, W. Tang, A. Xu, H. Yang, M. Huang, J. Lan, X. Li, **W. Duan**, C. Xu and S. Zhou, “Antitumor activity and underlying mechanisms of Ganopoly, the refined polysaccharides extracted from *Ganoderma Lucidum*, in mice”, *Immunological Investigations*, 34:171-198, 2005. (Impact Factor: 1.190; ERA: C). Times Cited: 18.

28. J. Li, S. Zhou, H. Huynh, **W. Duan**, E. Chan, “Alteration of the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, due to acute gastrointestinal toxicity of doxorubicin”, *Pharmaceutical Research*, 22:1954-1963, 2005 (Impact Factor; 2.940; ERA: A). Times Cited: 2.

29. X. Yang, Z. Hu, S. Y. Chan, P. Ho, E. Chan, **W. Duan**, B. C. Goh, and S. Zhou, “Determination of thalidomide by high performance liquid chromatography: plasma pharmacokinetic studies in the rat”, *J. Pharmaceutical and Biomedical Analysis*, 39:299-304., 2005. (Impact Factor 1.509; ERA: B). Times Cited: 8.

30. S. Zhou, M. Huang, A. Xu, H. Yang, **W. Duan** and J. W Paxton, “Prediction of herb-drug metabolic interactions: a simulation study”, *Phytotherapy Research*, 19:464-471, 2005. (Impact Factor: 0.975; ERA: B). Times Cited: 4.

31. X. Yang, Z. Hu, S. Y. Chan, B. C. Goh, **W. Duan**, E. Chan, S. Zhou, “Simultaneous determination of the lactone and carboxylate forms of irinotecan (CPT-11) and its active metabolite SN-38 by high performance liquid chromatography: application to plasma pharmacokinetic studies in the rat”, *J. Chromatogr. B*, 821:221-228, 2005 (Impact Factor: 2.176; ERA: B). Times Cited: 10.

32. P. Wang, **W. Duan**, A. L. Munn, H. Yang, “Molecular Characterization of Osh6p, an Oxysterol Binding Protein Homolog in the Yeast *Saccharomyces cerevisiae*”, *FEBS J.*, 272(18):4703-4715, 2005. (Impact Factor: 3.26; ERA: B). Times Cited: 9.

33. Y. Zhang, J. Ding, **W. Duan** and W. Fan, Influence of pulsed electromagnetic field with different pulse duties on neurite outgrowth in PC 12 rat pheochromocytoma cells”, *Bioelectromagnetics*. 26:406-411, 2005 [Impact factor: 1.243; ERA: A]. Times Cited: 7.

34. Y. Zhang, J. Ding and **W. Duan**, “A study of the effects of flux density and frequency of pulsed electromagnetic field on neurite outgrowth in PC12 cells”. *Journal of Biological Physics*, 32:1-9, 2006 (Impact Factor: 1.229; ERA: B). Times Cited: 0.

35. Q. Tian, J. Zhang, M. C. T. Tan, E. Chan, **W. Duan**, S. Y. Chan, U. A. Boelsterli, P. C.-L. Ho, H. Yang, J. Bian, M. Huang, Y.-Z. Zhu, W. Xiong, X. Li, and S. Zhou. “Human Multidrug Resistance Associated Protein 4 Confers Resistance to Camptothecins”, *Pharmaceutical Research*, 22:1837-1853, 2005 (Impact Factor; 2.940; ERA: A). Times Cited: 40.

36. Q. Tian, J. Zhang, S. Y. Chan, T. M. C. Tan, **W. Duan**, M. Huang, Y.-Z. Zhu, E. Chan, Q. Yu, Y.-Q. Nie, P. C.-L. Ho, Q. Li, L. K.-Y. Ng, H. Yang, H. Wei, J. Bian and S. Zhou. “Topotecan is a Substrate for Multidrug Resistance Associated Protein 4”, *Current Drug Metabolism*, 7:105-116, 2006. (Impact Factor: 4.737; ERA: A*). Times Cited: 19.

37. X. Chen, Z.-P. Hu, X.-X. Yang, M. Hang, Y. Gao, W. Tang, S. Y. Chan, Xihu Dai, J. Ye, P. C.-L. Ho, **Wei Duan**, H.-Y. Yang, Y.-Z. Zhu, and S.-F. Zhou. "Monitoring of immune responses to a herbal immuno-modulator in patients with advanced colorectal cancer", *International Immunopharmacology*, 6:499-508, 2006 (Impact Factor 1.827; ERA: B). Times Cited: 18.
38. Jefferey, S. Armstrong, Yee Liu Chua, Wawei Zhang, **Wei Duan**, Yih-Cherng Liou and Matthew Whiteman, "Nitric oxide blocks glutathione-dependent cell death independently of mitochondrial reactive oxygen species: Potential role of S-nitrosylation?" *Biochem. Biophys. Res. Commun.* 339: 255-262, 2006 (Impact Factor: 2.904; ERA: B). Times Cited: 17.
39. Minghui Jessica Chen, Yann Wan Yap, Meng Shyan Choy, Chor Hui Vivien Koh, Sze Jee Seet, **Wei Duan**, Matthew Whiteman and Nam Sang Cheung "Early Induction of Calpains In Rotenone-mediated Neuronal Apoptosis", *Neurosci. Lett.* 397:69-73. 2006 (Impact Factor: 2.019; ERA: C). Times Cited: 12.
40. Y. Zhu, D. Smith, C. Verma, W. G. Lim, B. J. Tan, J. S. Armstrong, S. Zhou, E. Chan, S.-L. Tan, Y.-Z. Zhu, N. S. Cheung and **Wei Duan**, "The very C-terminus of protein kinase C ϵ is critical for the full catalytic competence but its hydrophobic motif is dispensable for the interaction with 3-phosphoinositide-dependent kinase-1", *Cellular Signalling*, 18:807-818, 2006. (Impact Factor 5.185; ERA: B). Times Cited: 5.
41. Wee Guan Lim, Bee Jen Tan, Yimin Zhu, Shufeng Zhou, Jeffrey S. Armstrong, Qiu Tian Li, Qihan Dong, Eli Chan, Derek Smith, Chandra Verma, Seng-Lai Tan and **Wei Duan**, "The Very C-Terminus Of PRK1/PKN Is Essential For Its Activation By RhoA And Downstream Signaling", *Cellular Signalling*. 18(9):1473-1481, 2006 (Impact factor: 4.887; ERA: B). Times Cited: 5.
42. Shi-long Zhong, Shu-Feng Zhou, Xiao Chen, Eli Chan, Ka-Yun Ng, **Wei Duan**, and Min Huang, "Relationship between genotype and enzyme activity of glutathione S-transferases M1 and P1 in Chinese". *European Journal Of Pharmaceutical Sciences*, 28:77-85, 2006 (Impact Factor: 1.949; ERA: A). Times Cited: 18.
43. Xiao-Xia Yang, Ze-Ping Hu, Sui Yung Chan, **Wei Duan**, Eli Chan, Paul Chi-Liu Ho, Ka-Yun Ng, Jin-Song Bian, and Shu-Feng Zhou. "Pharmacokinetic mechanisms for reduced toxicity of irinotecan by coadministered thalidomide". *Current Drug Metabolism*, 7(4):431-455., 2006 (Impact Factor: 4.652; ERA A*). Times Cited: 2.
44. C.H.V. Koh, R.Z. Qi, D. Qu, A. Melendez, J. Manikandan, B.H. Bay, **W. Duan** and N.S. Cheung, "U18666A-mediated apoptosis in cultured murine cortical neurons: role of caspases, calpains and kinases", *Cellular Signalling*, 18(10):1572-1583, 2006 (Impact factor: 4.887; ERA: B). Times Cited: 9.
45. Eli Chan, Shufeng Zhou, Sahasranaman Srikumar and **Wei Duan**, "Use of in vitro critical inhibitory concentration, a novel approach to predict in vivo synergistic bactericidal effect of combined amikacin and piperacillin against *Pseudomonas aeruginosa* in a systemic rat infection mode", *Pharmaceutical Research*, 23(4):729-741. 2006. (Impact Factor; 2.940; ERA: A). Times Cited: 1.
46. Loh KP, Low LS, Wong WH, Zhou S, Huang SH, De Silva R, **Duan W**, Chou WH, Zhu YZ. "A comparison study of cerebral protection using Ginkgo biloba extract and Losartan on stroked rats", *Neurosci Lett.* 398:28-33, 2006 (Impact Factor: 2.019; ERA: C). Times Cited: 2.

47. Jing Zhang, Min Huang, Su Guan, Hui-chang Bi, Ying Pan, **Wei Duan**, Sui Yung Chan, Xiao Chen, Yun-Han Hong, Fin-song Bain, Hong-Yuan Yang and Shufeng Zhou, "A Mechanistic Study of the Intestinal Absorption of Cryptotanshinone, the Major Active Constituent of *Salviae miltiorrhizae*", *J. Pharmacol. Exp. Ther.*, 317(3):1285-1294, 2006. (Impact Factor = 4.3; ERA: A). Times Cited: 20.
48. X.-X. Yang, Z.-P. Hu, S.Y. Chan, **W. Duan**, E. Chan and S.F. Zhou, "Pharmacokinetics of recombinant human endostatin in rats", *Curr. Drug Metabolism*, 7(6):565-576, 2006. (Impact Factor: 4.652; ERA: A*). Times Cited: 1.
49. J. Chen, X-X. Yang, H. Min, Z.-P. HU, M. He, **W. Duan**, E. Chan, F.-S. Sheu, X. Chen, S.-F. Zhou, "Small Interfering RNA-mediated silencing of cytochrome P450 3A4 Gene", *Drug Metab. Dispos.* 34 (9):1650-1657. 2006. (Impact Factor: 3.836; ERA: A). Times Cited: 5.
50. L.-Z. Zhao, M. Huang, J. Chen, P.L. R. Ee, E. Chan, **W. Duan**, Y.-Y. Guan, Y.-H. Hong, X. Chen, F.-S. Sheu and S. Zhou. "Induction of propranolol metabolism by Ginkgo biloba extract EGb 761 in rats". *Curr. Drug Metabolism*, 7(6):577-587, 2006. (Impact Factor: 4.652; ERA: A*). Times Cited: 8.
51. X.-X. Yang, Z.P. Hu, S.Y. chan, A.-L. Xu, **W. Duan**, Y.-Z. Zhun, M. Huang, F.-S. Shan, U. A. Boelsterli, J.-S. Bian, E. Chan, X. Li, P.L.R. Ee and S.F. Zhou, "A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor- α inhibitor", *J. Pharmacol. Exp. Ther.*, 319(1): 82-104, 2006 (Impact Factor = 4.3; ERA: A). Times Cited: 5.
52. S. Guan, M. Huang, E. Chan, X. Chen, **W. Duan** and S.-F. Zhou. "Genetic polymorphisms of cytochrome P450 2B6 gene in Han Chinese". *Eur J Pharm Sci.* 29 (1):14-21, 2006 (Impact Factor: 2.347; ERA: A). Times Cited: 6.
53. Ke Shao, Qingsong Hou, **Wei Duan**, Mei Lin Go, Kim Ping Sit, Qiu-Tian Li. "Intra cellular drug delivery by sulfatide-mediated liposomes to gliomas". *Journal of Controlled Release*, 115(2):150-157., 2006, (Impact Factor = 4.012; ERA: A). Times Cited: 9.
54. Chang PN, Mao JC, Huang SH, Ning L, Wang ZJ, On T, **Duan W**, Zhu YZ. Analysis of cardioprotective effects using purified *Salvia miltiorrhiza* extract on isolated rat hearts.", *J Pharmacol Sci.* 101(3):245-249, 2006. (Impact Factor = 1.792; ERA: A). Times Cited: 18.
55. S.S. Yeong, Y. Zhu, D. Smith, C. Verma, W. G. Lim, B. J. Tan, Q. T. Li, N. S. Cheung, M. Cai, Y.-Z. Zhu, S.-F. Zhou, S.-L. Tan and **Wei Duan**, "The Last Ten Amino Acid Residues Beyond The Hydrophobic Motif Are Critical For The Catalytic Competence And Function Of Protein Kinase C α ", *J. Biol. Chem.* 281(41):30768-30781, 2006. (Impact Factor = 5.854; ERA A*). Times Cited: 7.
56. Hu ZP, Yang XX, Chan SY, Xu AL, **Duan W**, Zhu YZ, Sheu FS, Boelsterli UA, Chan E, Zhang Q, Wang JC, Ee PL, Koh HL, Huang M, Zhou SF. " St. John's wort attenuates irinotecan-induced diarrhea via down-regulation of intestinal pro-inflammatory cytokines and inhibition of intestinal epithelial apoptosis", *Toxicol Appl Pharmacol.* 216(2):225-237, 2006. (Impact Factor: 3.148; ERA: A). Times Cited: 10.

57. Zhong S, Huang M, Yang X, Liang L, Wang Y, Romkes M, **Duan W**, Chan E, Zhou SF. "Relationship of glutathione S-transferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus." *Br J Clin Pharmacol*. 62(4):457-472, 2006. (Impact Factor: 2.546; ERA: A). Times Cited: 13.
58. K. Shao, Q. Hou, M.L. Go, **Wei Duan**, N.S. Cheung, S.-S. Feng, K.P. Wong, A. Yoram, W. Zhang, Z. Huang & Q.-T. Li, "Sulfatide-tenascin interaction mediates binding to the extracellular matrix and endocytic uptake of liposomes in glioma cells", *Cellular and Mol Life Sciences*, 64:506-515, 2007. (Impact Factor: 4.582; ERA: A). Times Cited: 2.
59. X.-Y. Yu, S.-G. Lin, Z.-W. Zhou, X. Chen, J. Liang, P.-Q. Liu, **Wei Duan**, B. Chowbay, S.-F. Zhou, "Role of P-Glycoprotein in the Intestinal Absorption of Tanshinone IIA, a Major Active Ingredient in the root of *Salvia miltiorrhiza* Bunge", *Current Drug Metabolism*, 8(4):325-340, 2007. (Impact Factor: 5.416; ERA A*). Times Cited: 10.
60. X. Yu, Z.-W. Zhou, S.-G. Lin, X. Chen, X.-Q. Yu, J. Liang, M. Huang, **Wei Duan**, J.-Y. Wen, X.-T. Li, S.-F. Zhou, "Role of ATP-Binding Cassette Drug Transporters in the Intestinal Absorption of Tanshinone IIB, One of the Major Active Diterpenoids from the Root of *Salvia miltiorrhiza*", *Xenobiotica*, 37(4):375-415, 2007, (Impact Factor: 1.427; ERA: B). Times Cited: 5.
61. Yu XY, Lin SG, Zhou ZW, Chen X, Liang J, Yu XQ, Chowbay B, Wen JY, **Duan W**, Chan E, Li XT, Cao J, Li CG, Xue CC, Zhou SF., "Role of P-glycoprotein in limiting the brain penetration of glabridin, an active isoflavan from the root of *Glycyrrhiza glabra*." *Pharm. Res.* 24(9):1668-1690, 2007. (Impact Factor: 2.752; ERA: A). Times Cited: 8.
62. Hu ZP, Yang XX, Chen X, Chan E, **Duan W**, Zhou SF. "Simultaneous determination of irinotecan (CPT-11) and SN-38 in tissue culture media and cancer cells by high performance liquid chromatography: Application to cellular metabolism and accumulation studies". *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.* 850(1-2):575-580, 2007. (Impact Factor: 2.391; ERA: B). Times Cited: 5.
63. Hu ZP, Yang XX, Chen X, Cao J, Chan E, **Duan W**, Huang M, Yu XQ, Wen JY, Zhou SF, "A Mechanistic Study on Altered Pharmacokinetics of Irinotecan by St. John's Wort", *Curr. Drug Metab.* 8:157-171, 2007. (Impact Factor: 5.416; ERA A*). Times Cited: 8.
64. X.-Y. Yu, S.-G. Lin, Z.-W. Zhou, X. Chen, J. Liang, **W. Duan**, X.-Q. Yu, J.-Y. Wen, B. Chowbay, C.-G. Li, F.-S. Sheu, E. Chan, S.-F. Zhou "Tanshinone IIB, a Primary Active Constituent from *Salvia miltiorrhiza*, Exhibits Neuro-protective Activity in Experimentally Stroked Rats", *Neurosci. Lett.* 417(3):261-265, 2007. (IF=2.092; ERA: C). Times Cited: 7.
65. X.-Y. Yu, S.-G. Lin, X. Chen, Z.-W. Zhou, J. Liang, **Wei Duan**, B. Chowbay, J.-Y. Wen, E. Chan, J. Cao, C.-G. Li and S-F Zhou. "Transport of cryptotanshinone, a major active constituent in *Salvia miltiorrhiza* Bunge widely used in the treatment of stroke and Alzheimer's disease, across the blood-brain barrier". *Curr. Drug Metab.* 8(4):365-378, 2007. (Impact Factor: 5.416; ERA: A*). Times Cited: 10.
66. M.J. Stewart, N. Soonklang, P. Stewart, P. J. Hanna, C. Wanichanon, A. Parratt, **W. Duan** and P. Sobhon, "Histological studies of the ovaries of two tropical portunid crabs, *Portunus pelagicus* (L.) and *Scylla serrata* (F.)", *Invertebrate Reproduction & Development*, 50(2):85-97, 2007 (IF= 0.562; ERA: C). Times Cited: 1.

67. Zhang W, **Duan W**, Cheung NS, Huang Z, Shao K, Li QT., "Pituitary adenylate cyclase-activating polypeptide induces translocation of its G-protein-coupled receptor into caveolin-enriched membrane microdomains, leading to enhanced cyclic AMP generation and neurite outgrowth in PC12 cells." *J. Neurochem.* 103(3):1157-1167, 2007 (IF=4.260; REA: A). Times Cited: 9.
68. Cao J, Chen X, Liang J, Yu XQ, Xu AL, Chan E, **Duan, Wei**, Huang M, Wen JY, Yu XY, Li XT, Sheu FS, Zhou SF. "Role of P-glycoprotein in the intestinal absorption of glabridin, an active flavonoid from the root of *Glycyrrhiza glabra*.", *Drug Metabolism and Disposition.* 35(4):539-553, 2007. (IF= 3.907, ERA: A), Times Cited: 12.
69. Dakang Xu, Julie Dwyer, He Li, **Wei Duan**, and Jun-Ping Liu , "ETS2 maintains hTERT gene expression and breast cancer cell proliferation by interacting with c-myc". *J. Biol. Chem.*, 283:23567-80, 2008. (IF=5.581; ERA A*). Times Cited. 10.
70. W. G. Lim, X. Chen, J.-P. Liu, B. J. Tan, S. Zhou, A. Smith, N. Lees, L. Hou, F. Gu, X. Y. Yu, Y. Du, D. Smith, C. Verma, K. Liu and **Wei Duan**, "The C-terminus of PRK2/PKN γ is required for optimal activation by RhoA in a GTP-dependent manner", *Arch. Biochem. Biophys.*, 479(2):170-178, 2008, (IF=2.578; ERA: B). Times Cited: 1..
71. W. Zhang, A. Smith, J.-p. Liu, N. S. Cheung, S. Zhou, K. Liu, Q.-T. Li* and **Wei Duan**, "GSK3 β modulates PACAP-induced neuritogenesis in PC12 cells by acting downstream of Rap1 in a caveolae-dependent manner", *Cellular Signalling*, 21:237-245, 2009. (IF=4.305; ERA: B). Times Cited: 4.
72. H. Cao, Y. Wang, Y. Zhong, X. Liu, M. Miao, **Wei Duan***, K. Liu* (*Co-corresponding author), "YPK1 overexpression resulted salt stress hypersensitivity in *Saccharomyces cerevisiae* is dependent on TOR1", *Acta Microbiologica Sinica*, 49 (8) :1069 - 1074 , 2009.
73. J. Du, D. Z. Fang, J. Lin, L. Y. Xiao, X. D. Zhou, S. Shigdar and **Wei Duan**, "TaqIB polymorphism in the cholesterol ester transfer protein (CETP) gene modulates the impact of HC/LF diet on the HDL profile in healthy Chinese young adults", *The Journal of Nutritional Biochemistry.* 21:1114-1119, 2010. (IF= 4.352; ERA: A*).
74. M.J. Stewart, P. Stewart, Nn Soonklang, V. Linthong, P. J. Hanna, **Wei Duan**, P. Sobhond, "Spermatogenesis in the blue swimming crab, *Portunus pelagicus*, and evidence for histones in mature sperm nuclei", *Tissue and Cell*, 42(3):137-150, 2010. (IF=0.738; ERA: C)
75. YH Liu, SL Mo, HC Bi, BF Hu, CG Li, YT Wang, LH Huang, M Huang, **W Duan**, JP Liu, MQ Wei, SF Zhou, "Regulation of Human Pregnane X Receptor and its Target Gene Cytochrome P450 3A4 by Chinese Herbal Compounds and A Molecular Docking Study", *Xenobiotica* 2011, in press. (IF=2,8, ERA: B),
76. S Shigdar, J Lin, Y Yu, M Pastuovic, M Wei, and **Wei Duan**. "An RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule (EpCAM)", *Cancer Sci.*, 2011 Feb 1. doi: 10.1111/j.1349-7006.2011.01897.x. [Epub ahead of print] (ERA: A, IF=3.771).